Launch of Aflibercept kit for IVT inj. 40 mg/mL Bayer
January 9, 2026, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (head office: Osaka, Japan; hereinafter Santen) announced that it will launch the ophthalmic Vascular Endothelial Growth Factor (VEGF) inhibitor, Aflibercept kit for IVT inj. 40 mg/mL Bayer on February 2, 2026 in Japan, for which Bayer Life Science Ltd. has received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare (MHLW).
This bioidentical product has the same active ingredient, excipients, and manufacturing process as the VEGF inhibitor, Eylea® kit for IVT inj. 40 mg/mL, for which Bayer Yakuhin Ltd. (Head office: Osaka, Japan; hereinafter Bayer Yakuhin) previously obtained manufacturing and marketing authorization, and which Bayer Yakuhin and Santen have been providing information, with Santen handling distribution and sales in Japan. This product has four indications: age-related macular degeneration with subfoveal choroidal neovascularization, macular edema secondary to retinal vein occlusion, choroidal neovascularization in pathologic myopia, and diabetic macular edema. Santen is responsible for promotional activities to medical institutions, as well as distribution and sales of the product.
Through the distribution of this product, Santen aims to meet the diverse needs of patients in the field of retinal diseases and contribute to treatments that enhance quality of life.
| Brand name | Aflibercept kit for IVT inj. 40 mg/mL Bayer |
| INN name | aflibercept (recombinant) |
| Indications | Age-related macular degeneration with choroidal neovascularization Macular edema secondary to retinal vein occlusion Choroidal neovascularization in pathologic myopia Diabetic macular edema |
| Dosage and Administration | <Age-related macular degeneration with subfoveal choroidal neovascularization> 2 mg (0.05 mL) of aflibercept (recombinant) administered intravitreally once every month for 3 consecutive months (loading dose period). In the maintenance period, the drug is usually administered by intravitreal injection once every 2 months. The dosing interval should be adjusted according to symptoms as needed but should be 1 month or longer. <Macular edema secondary to retinal vein occlusion, choroidal neovascularization in pathologic myopia> 2 mg (0.05 mL) of aflibercept (recombinant) administered intravitreally. The dosing interval should be at least 1 month. <Diabetic macular edema> 2 mg (0.05 mL) of aflibercept (recombinant) administered intravitreally once every month for 5 consecutive months. Subsequently, the drug is usually administered by intravitreal injection once every 2 months. The dosing interval should be adjusted according to symptoms as needed but should be 1 month or longer. |
| National Health Insurance price | 69,894 yen |
| Date of NHI price listing | December 5, 2025 |
| Date of launch | February 2, 2026 |
| Manufactured and marketed by | Bayer Life Science Ltd. |
| Distributed by | Santen Pharmaceutical Co., Ltd. |
<Product Photograph>
About Santen
Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen’s products and services are available in more than 60 countries and regions. Guided by its Core Principle “Tenki ni sanyo suru” – Exploring the secrets and mechanisms of nature in order to contribute to people’s health – Santen combines its expertise with deep patient focus to contribute to the realization of “Happiness with Vision.”
For more information, please visit https://www.santen.com/en.
About Bayer Life Science
Bayer Life Science Ltd. is a wholly-owned subsidiary of Bayer Holding Ltd., specializing in the manufacturing and marketing of pharmaceutical products. The company offers life science solutions for patients and healthcare professionals, addressing the evolving demands of society, healthcare needs, and technological advancements. For further information, please visit www.bayer.jp/ja/bayerlifescience.
Contact
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com
Official SNS
